Cytosorbents Corp
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
CTSO$5.83+21.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · At December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| ASSETS · · · · · | ||||||
| Current Assets: · · · · · | ||||||
| Cash and cash equivalents | | $6,249 | | $3,280 | ||
| Restricted cash, current | | | — | | | 5,000 |
| Accounts receivable, net of allowances of $164 and $158 at December 31, 2025 and 2024, respectively | | 7,550 | | 7,320 | ||
| Inventories - net | | 5,281 | | 2,733 | ||
| Prepaid expenses and other current assets | | 1,554 | | 3,271 | ||
| Total current assets | | 20,634 | | 21,604 | ||
| | | | | | ||
| Property and equipment - net | | 7,823 | | 9,002 | ||
| Restricted cash | | | 1,522 | | | 1,484 |
| Right-of-use asset | | | 10,924 | | | 11,511 |
| Patents - net | | | 3,226 | | | 3,721 |
| Other assets | | 53 | | 50 | ||
| Total Assets | | $44,182 | | $47,372 | ||
| | | | | | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | ||
| Current Liabilities: | | | | | ||
| Accounts payable | | $2,869 | | $3,340 | ||
| Accrued expenses and other current liabilities | | 6,299 | | 6,032 | ||
| Lease liability – current portion | | | 541 | | | 453 |
| Total current liabilities | | 9,709 | | 9,825 | ||
| Lease liability, net of current portion | | | 11,903 | | | 12,444 |
| Long-term debt, net of debt discount | | 16,667 | | 13,996 | ||
| Total Liabilities | | 38,279 | | 36,265 | ||
| | | | | | ||
| Commitments and Contingencies | | | | | ||
| Stockholders’ Equity: | | | | | ||
| Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024 | | | — | | | — |
| Common Stock, Par Value $0.001, 100,000,000 shares authorized; and 62,804,305 and 54,830,146 shares issued and outstanding at December 31, 2025 and 2024, respectively | | 63 | | 55 | ||
| Additional paid-in capital | | 321,024 | | | 310,809 | |
| Accumulated other comprehensive income (loss) | | (2,977) | | | 4,252 | |
| Accumulated deficit | | (312,207) | | | (304,009) | |
| Total Stockholders’ Equity | | 5,903 | | | 11,107 | |
| Total Liabilities and Stockholders’ Equity | | $44,182 | | $47,372 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.